Arcadia Biosciences Capital Expenditures (CapEx) Growth & History (RKDA)

Arcadia Biosciences's capital expenditures (capex) was $0 for fiscal 2025.

View full Arcadia Biosciences company overview

Arcadia Biosciences annual capital expenditures (capex) history

Arcadia Biosciences annual capital expenditures (capex)

Fiscal yearPeriod endedCapital expenditures (CapEx)ChangeGrowth
20252025-12-31$0−$16,000
20242024-12-31$16,000$11,000+220.00%
20232023-12-31$5,000−$67,000−93.06%
20222022-12-31$72,000−$935,000−92.85%
20212021-12-31$1.0M−$1.3M−56.87%
20202020-12-31$2.3M$858,000+58.09%
20192019-12-31$1.5M$1.2M+490.80%
20182018-12-31$250,000$171,000+216.46%
20172017-12-31$79,000−$152,000−65.80%
20162016-12-31$231,000$80,000+52.98%
20152015-12-31$151,000$3,000+2.03%
20142014-12-31$148,000

Arcadia Biosciences capital expenditures (capex) trends

Over the last five fiscal years, Arcadia Biosciences's capital expenditures (capex) decreased from $2.3M to $0, a change of −$2.3M. The latest reported quarter, Q4 2025, shows $0.

About the metric

What capital expenditures (CapEx) mean

Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.

Calculation and source

SEC-reported capital expenditures

TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Arcadia Biosciences source filings ↗

Community posts

It’s quiet here.

No posts about RKDA yet. Start the conversation.

Write the first post